Skip to content
Peptigraph home
Shop Peptides50% off*

How to Inject Cagrilintide: Sites, Syringes and Steps

Where to inject Cagrilintide, which syringe to use, how to read units and the hygiene steps that prevent infection.

Medical review pendingAmylin analogUpdated
This is a general guide to subcutaneous injection, not a substitute for being shown by a nurse, pharmacist or doctor.

Injection sites

Most peptides are injected under the skin (subcutaneously), into the fatty layer rather than the muscle.

  • Belly: at least 2 inches (5 cm) away from the navel.
  • Front and outer thighs.
  • Back of the upper arms, if someone else can reach it.
  • Rotate sites each time and avoid skin that is bruised, scarred or irritated.

Syringe and needle

U-100 insulin syringes are marked in units: 100 units equal 1 mL, so 10 units is 0.1 mL. They come in 0.3, 0.5 and 1 mL sizes; a smaller syringe has finer marks and is easier to read for small doses. Needle length and gauge used for Cagrilintide in studies: not reported in study abstracts (PubMed search, 11 Oct 2026).

How to read an insulin syringe

Step by step

  1. 1Wash your handsUse soap and water, and work on a clean surface.
  2. 2Check the vialLabel, lot and date present; solution clear with no particles. Mixing a powder vial first? Use sterile bacteriostatic water.
  3. 3Clean the vial top and the siteWipe both with an alcohol swab and let them dry.
  4. 4Draw the dosePull the plunger to the units mark for your dose, then tap out air bubbles and re-check the mark.
  5. 5InjectPinch a fold of skin, insert the needle at 45 to 90 degrees, push the plunger slowly and wait a few seconds before withdrawing.
  6. 6Dispose safelyPut the used syringe straight into a sharps container. Never reuse or share needles.
How to reconstitute a peptide vial

How the trials gave cagrilintide

The type 2 diabetes trial gave cagrilintide by once-weekly subcutaneous injection, escalated to 2.4 mg.[8]

The thorough QT study also used a once-weekly subcutaneous injection, escalated to 4.5 mg.[9]

In the mouse study the injections were subcutaneous and given once a day (SID); the dose was 3 nmol/kg. This is animal data.[10]

No label to follow

There is no approved cagrilintide product: the Drugs@FDA lookup of 2026-10-02 found nothing, so there is no label with injection-site, rotation or pen instructions to quote.[11]

The pharmacokinetic study that gave single doses reports only exposure and safety outcomes in kidney and liver impairment, not injection technique.[12]

Common questions

Where do you inject Cagrilintide?

Under-the-skin (subcutaneous) injections are usually given in the belly, at least 2 inches from the navel, the front of the thighs or the back of the upper arms. Rotate sites each time.

What syringe is used for Cagrilintide?

Vials are usually drawn with a U-100 insulin syringe, where 100 units equal 1 mL. Common sizes hold 0.3, 0.5 or 1 mL. Match the syringe to the dose so the mark is easy to read.

How often is Cagrilintide injected?

The interval comes from the study or prescription, not from this guide. See the dosage page for what studies used.

More on Cagrilintide

DosageDoses used in published studies, with the source for each.CalculatorVial, water and dose to syringe units.Side effectsWhat labels and studies report, and what is unknown.ResultsStudy outcomes and when they were measured.BenefitsClaimed benefits next to what published studies measured.How it worksTarget, mechanism and how long it acts, from the label or studies.

Sources

  1. 1Metric (SI) Prefixes (NIST Reference on Constants, Units, and Uncertainty)National Institute of Standards and Technology (NIST) · 2025physics.nist.govAccessed 2 Oct 2026
  2. 2BASAGLAR (insulin glargine) injection, prescribing information (DailyMed)U.S. Food and Drug Administration / DailyMed (Eli Lilly and Company label) · 2026dailymed.nlm.nih.govAccessed 2 Oct 2026
  3. 3PubMed search: cagrilintide[tiab] OR cagrisema[tiab] OR "cagrilintide and semaglutide"[tiab] (118 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  4. 4PubMed search: (cagrilintide[tiab] OR cagrisema[tiab]) AND (randomized[tiab] OR trial[tiab] OR phase[tiab]) (58 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  5. 5PubMed search: (cagrilintide[tiab] OR cagrisema[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (10 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  6. 6PubMed search: cagrilintide[tiab] AND semaglutide[tiab] AND "Randomized Controlled Trial"[pt] (13 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  7. 7PubMed search: (cagrilintide[tiab] OR cagrisema[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (62 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
  8. 8Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial.Lancet (London, England) · 2023PMID 37364590Accessed 11 Oct 2026
  9. 9Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants.Diabetes, obesity & metabolism · 2024PMID 39279639Accessed 2 Oct 2026
  10. 10Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3.EBioMedicine · 2025PMID 40609154Accessed 2 Oct 2026
  11. 11Drugs@FDA (openFDA) search: active ingredient "cagrilintide"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
  12. 12Renal or Hepatic Impairment Does Not Affect Pharmacokinetics, Safety, or Tolerability of Subcutaneous Cagrilintide.Clinical pharmacokinetics · 2026PMID 42228334Accessed 2 Oct 2026

Found an error? Report a correction.